Lamotrigine 25

PreclinicalSmall molecule

GSK

Lamotrigine 25 is one of 11 small molecule programs targeting Suicide. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SuicideActive, not recruiting

SuicidePreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Suicide

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

6 2

Estrace

Spravato

2 4

Suboxone

IIndivior Inc.

Approved

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Approved

1 6

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 7

Zyprexa

MMODAG GmbH

Approved

1 8

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 9

D-Cycloserine

MMassachusetts General Hospital

Phase 2

1 10

Lithobid

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pregnancy2 trials

Lamotrigine Pregnancy Registry (LAM05)

Completed· GSK logo

GSK··NCT01064297·3,416 enrolled

Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)

Completed· GSK logo

GSK··NCT01055327·1 enrolled

MPR2 trials

The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects

Completed· GSK logo

GSK·Phase 1·NCT01879423·24 enrolled

The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg

Completed· GSK logo

GSK·Phase 1·NCT02064465·138 enrolled

LAM2 trials

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00449774·220 enrolled

Bioequivalence and Food Effect of 250mg of Lamotrigine XR

Completed· GSK logo

GSK·Phase 1·NCT00605371·209 enrolled

Epilepsy1 trial

Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study

Completed· GSK logo

GSK·Phase 4·NCT02100644·33 enrolled

Suicide1 trial

WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide

Completed· GSK logo

GSK··NCT01607333·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Lamotrigine 25. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lamotrigine 25 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lamotrigine 25. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Lamotrigine 25

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pregnancy2 trials

MPR2 trials

LAM2 trials

Epilepsy1 trial

Suicide1 trial

References

Drug Info

Quick Facts

Related News